Predictors for reimbursement of oncology drugs in Belgium between 2002 and 2013

Abstract

Evidence-based medicine still plays a role in Belgian reimbursement decision-making. In order to allow transition towards value-based medicine and avoid spending money on products with limited incremental benefit, therapeutic need at patient level need to be taken into account.